Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy

Abstract

Radiopharmaceutical therapy (RPT) is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, representing a breakthrough strategy for cancer treatment. Radiopharmaceuticals typically consist of a small amount of radioactive material, a radionuclide, paired with a chemical that specifically targets the cell. Some radionuclides naturally target specific cells or biological processes without the need for modification. RPT is a novel cancer treatment method that offers various advantages over current traditional treatment approaches. One of the primary advantages of RPT is its ability to target cancer cells, including those in metastatic areas. Another key advantage of RPT is that radiation can be delivered systemically, locally, or physiologically to specific cells internally rather than being applied externally. Moreover, radiotracer imaging can be utilized to determine radiopharmaceutical absorption in target tissues before providing a therapeutic dose. Compared to all other cancer treatment approaches, RPT has demonstrated high efficacy with minimal toxicity. The recent approval of multiple RPT medicines by the US Food and Drug Administration highlights the tremendous potential of this treatment. This article provides a detailed review of RPT, including insights into manufacturing procedures, safetymeasures, and its applications in cancer therapy.

Keywords

radiopharmaceutical therapy / radiopharmaceuticals / quality control / scintigraphy

References

[1] Sgouros G. Radiopharmaceutical Therapy. Health Phys. 2019;116(2):175-178.

[2] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589-608.

[3] Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules. 2022;27(16):5231.

[4] Abbott EM, Falzone N, Lenzo N, Vallis KA. Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks. Clin Oncol (R Coll Radiol). 2021;33(11):735-743.

[5] Vernekar S, Budha RR, Alavala RR. Radiopharmaceuticals: A New Vista forDiagnosis and Treatment of Thyroid Cancer. Curr Radiopharm. 2024;17(2):148-162.

[6] Kipper SL, Rypins EB, Evans DG, Thakur ML, Smith TD, Rhodes B. Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J Nucl Med. 2000;41(3):449-455.

[7] Matsumoto K, Fujibayashi Y, Konishi J, Yokoyama A. Radiolabeling and biodistribution of 62Cu-dithiocarbamate–an application for the new 62Zn/62Cu generator. Radioisotopes. 1990;39(11):482-486.

[8] Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011;21(2):88-100.

[9] Marshall SK, Prom-On P, Sangkue S, Thiangsook W. Assessment of Radiation Exposure in a Nuclear Medicine Department during 99mTc-MDPBone Scintigraphy. Toxics. 2023;11(10):814.

[10] Talip Z, Favaretto C, Geistlich S, Meulen NPV. A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with 68Ga, 44Sc, 177Lu and 161Tb. Molecules. 2020;25(4):966.

[11] Gillings N, Hjelstuen O, Ballinger J, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6(1):8.

[12] Elsinga P, Todde S, Penuelas I, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37(5):1049-1062.

[13] Rao C, Hu Q, Ma J, et al. Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. J Exp Clin Cancer Res. 2010;29(1):7.

[14] Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules. 2022;27(16):5231. Published 2022 Aug 16.

[15] Herrmann K, Schwaiger M, Lewis JS, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146-e156.

[16] Spencer RP. Applied principles of radiopharmaceutical use in therapy. Int J Rad Appl Instrum B. 1986;13(4):461-463.

[17] Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol. 2010;73(3):461-469.

[18] Neves M, Kling A, Lambrecht RM. Radionuclide production for therapeutic radiopharmaceuticals. Appl Radiat Isot. 2002;57(5):657-664.

[19] Dhoundiyal S, Srivastava S, Kumar S, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur JMed Res. 2024;29(1):26.

[20] Boopathi E, Den RB, Thangavel C. Innate Immune System in the Context of Radiation Therapy for Cancer. Cancers (Basel). 2023;15(15):3972.

[21] Molavipordanjani S, Hosseinimehr SJ. Fundamental concepts of radiopharmaceuticals quality controls. Pharm Biomed Res. 2018;4(3):1-8.

[22] Gillings N, Hjelstuen O, Behe M, et al. EANM guideline on quality risk management for radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49(10):3353-3364.

[23] Lau J, Rousseau E, Kwon D, Lin KS, Bénard F, Chen X. Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers (Basel). 2020;12(5):1312.

[24] Elsinga P, Todde S, Penuelas I, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37(5):1049-1062.

[25] Hooijman EL, Ntihabose CM, Reuvers TGA, et al. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA. EJNMMI Radiopharm Chem. 2022;7(1):29.

[26] Laferriere-Holloway TS, Rios A, Carlucci G, van Dam RM. Rapid Purification and Formulation of Radiopharmaceuticals via Thin-Layer Chromatography. Molecules. 2022;27(23):8178.

[27] Wang J, Rios A, Lisova K, Slavik R, Chatziioannou AF, van Dam RM. High-throughput radio-TLCanalysis. Nucl Med Biol. 2020;82-83:41-48.

[28] Korde A, Patt M, Selivanova SV, et al. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI Radiopharm Chem. 2024;9(1):2.

[29] Gillings N, Hjelstuen O, Ballinger J, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6(1):8.

[30] Hu J, Li H, Sui Y, Du J. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 2022;49(8):2514-2530.

[31] Tang Y, Li S, Yang Y, et al. A simple and convenient method for production of 89Zr with high purity. Appl Radiat Isot. 2016;118:326-330.

[32] Gomes Marin JF, Nunes RF, Coutinho AM, et al. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics. 2020;40(6):1715-1740.

[33] Shah HJ, Ruppell E, Bokhari R, et al. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review. Eur J Radiol Open. 2023;10:100477.

[34] Wang Q, Shao X, Zhang Y, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149-11165.

[35] Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnology. 2019;17(1):90. Published 2019 Aug 21.

[36] Crişan G, Moldovean-Cioroianu NS, Timaru DG, Andrieş G, Căinap C, Chiş V. Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. Int J Mol Sci. 2022;23(9):5023.

[37] Solaro R, Chiellini F, Battisti A. Targeted Delivery of Protein Drugs by Nanocarriers. Materials. 2010;3(3):1928-1980.

[38] Li J, Wang Q, Xia G, et al. Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics. 2023;15(9):2233.

[39] Wu S, Helal-Neto E, Matos APDS, et al. Radioactive polymeric nanoparticles for biomedical application. Drug Deliv. 2020;27(1):1544-1561.

[40] Yao Y, Zhou Y, Liu L, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020;7:193.

[41] Camus B, Cottereau AS, Palmieri LJ, et al. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J Clin Med. 2021;10(6):1267.

[42] George SC, Samuel EJJ. Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Front Chem. 2023;11:1218670. Published 2023 Jul 31.

[43] Feijtel D, de Jong M, Nonnekens J. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward. Curr Top Med Chem. 2020;20(32):2959-2969.

[44] Patel CM, Wadas TJ, Shiozawa Y. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases. Molecules. 2021;26(8):2162.

[45] Islam MS, Fan J, Pan F. The power of phages: revolutionizing cancer treatment. Front Oncol. 2023;13:1290296.

[46] Shams M, Abdallah S, Alsadoun L, Hamid YH, Gasim R, Hassan A. Oncological Horizons: The Synergy of Medical and Surgical Innovations in Cancer Treatment. Cureus. 2023;15(11):e49249.

[47] Nelson BJB, Andersson JD, Wuest F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics. 2020;13(1):49.

[48] Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969-2992.

[49] Khan S, Syed A, Ahmad R, Rather TA, Ajaz M, Jan F. Radioactive waste management in a hospital. Int J Health Sci (Qassim). 2010;4(1):39-46.

[50] Gillings N, Hjelstuen O, Ballinger J, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6(1):8.

[51] Funeh CN, Bridoux J, Ertveldt T, et al. Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy. Pharmaceutics. 2023;15(5):1378.

[52] Levy F, Mareiniss D, Iacovelli C, Howard J. The Patient Safety and Quality Improvement Act of 2005 [published correction appears in J Leg Med. 2011 Jan;32(1):137. Mareniss, Darren [corrected to Mareiniss, Darren]]. J Leg Med. 2010;31(4):397-422.

[53] Pawłowska Z. Using lagging and leading indicators for the evaluation of occupational safety and health performance in industry. Int J Occup Saf Ergon. 2015;21(3):284-290.

[54] Yeong CH, Cheng MH, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B. 2014;15(10):845-863.

[55] Schreuder N, de Romijn I, Jager PL, Kosterink JGW, van Puijenbroek EP. Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. EJNMMI Radiopharm Chem. 2021;6(1):27.

[56] Cutler CS, Bailey E, Kumar V, et al. Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. J Nucl Med. 2021;62(3):422-430.

[57] Gutierrez-Barrios A, Cañadas-Pruaño D, Noval-Morillas I, Gheorghe L, Zayas-Rueda R, Calle-Perez G. Radiation protection for the interventional cardiologist: Practical approach and innovations. World J Cardiol. 2022;14(1):1-12.

[58] Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules. 2022;27(16):5231.

[59] Weber GF. DNA Damaging Drugs. Mol Ther Cancer. 2014;8:9-112.

[60] Beauregard JM. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer Imaging. 2022;22(1):67.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.